Engagement of Altimmune at Notable Investor Conferences Ahead

Author: Olivia Taylor Updated: 05-14-2025 07:49 AM

Altimmune to Present at Significant Investor Conferences

GAITHERSBURG, Md. — Altimmune, Inc. (Nasdaq: ALT), a pioneering biopharmaceutical company, is dedicated to developing innovative peptide-based therapeutics targeting liver and cardiometabolic disorders. The Company is gearing up for participation in two noteworthy investor conferences, where members of its management team will engage with attendees and conduct one-on-one meetings.

Upcoming Conference Details

Altimmune's presence at these events marks an opportunity for investors to gain insights into the company's advancements and strategic vision. The conferences include:

H.C. Wainwright 3rd Annual BioConnect Investor Conference

Scheduled for May 20, this conference located in New York will feature a fireside chat at 10:00 a.m. Eastern Time, providing a platform for Altimmune to share its progress and future aspirations.

Jefferies Global Healthcare Conference

On June 4, Altimmune will participate in another significant event in New York, with a fireside chat set for 9:55 a.m. Eastern Time. This engagement will further highlight the Company’s commitment to investors and stakeholders in the healthcare community.

Accessing the Presentations

The sessions will be streamed live, allowing interested parties to follow along and engage with the presented content. For those wishing to view the presentations, the webcast can be accessed via the Events section of the Altimmune website, ensuring everyone can stay informed about the latest developments in the company's research and initiatives.

About Altimmune and Its Innovations

Altimmune is at the forefront of developing forward-thinking biopharmaceutical solutions. The Company’s leading program, pemvidutide, is gaining notoriety as a dual GLP-1/glucagon receptor agonist and is instrumental in treating conditions such as metabolic-associated steatotic liver disease (MASH), obesity, Alcohol Use Disorder (AUD), and Alcohol Liver Disease (ALD). These therapeutic innovations highlight Altimmune's pivotal role in combating significant health challenges.

Discover more about the groundbreaking work at Altimmune by visiting their official website or social media channels.

Company Contacts

If you have inquiries regarding company updates or investor relations, feel free to reach out to:

Company Contact:

Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
Email: ir@altimmune.com

Investor Contact:

Lee Roth
Burns McClellan
Phone: 646-382-3403
Email: lroth@burnsmc.com

Media Contact:

Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
Email: Jake.robison@inizioevoke.com

Frequently Asked Questions

What is the main focus of Altimmune?

Altimmune focuses on developing innovative peptide-based therapeutics aimed at treating liver and cardiometabolic diseases.

When are the upcoming conferences Altimmune will attend?

Altimmune will participate in the H.C. Wainwright BioConnect Conference on May 20, followed by the Jefferies Global Healthcare Conference on June 4.

How can I access Altimmune’s presentations during the conferences?

The presentations will be available via live stream on Altimmune's website under the Events section.

What is pemvidutide?

Pemvidutide is Altimmune’s lead therapeutic program, designed as a dual GLP-1/glucagon receptor agonist that targets conditions like obesity and liver diseases.

How can I get in touch with Altimmune for investor queries?

Investors can contact Greg Weaver, the CFO, at 240-654-1450 or via email at ir@altimmune.com.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.